CoChat

Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Reliable biomarkers of frontotemporal dementia (FTD) are currently lacking. FTD may be associated with chronic immune dysfunction, microglial activation and raised inflammatory markers, particularly in progranulin (GRN) mutation carriers. Levels of soluble triggering receptor expressed on myeloid cells 2 (sTREM2) are elevated in Alzheimer's disease (AD), but they have not been fully explored in FTD. METHODS: We investigated whether cerebrospinal fluid (CSF) sTREM2 levels differ between FTD and controls, across different clinical and genetic subtypes of FTD, or between individuals with FTD due to AD versus non-AD pathology (based on CSF neurodegenerative biomarkers). We also assessed relationships between CSF sTREM2 and other CSF biomarkers (total tau [T-tau], tau phosphorylated at position threonine-181 [P-tau] and β-amyloid 1-42 [Aβ42]) and age and disease duration. Biomarker levels were measured using immunoassays in 17 healthy controls and 64 patients with FTD (behavioural variant FTD, n = 20; primary progressive aphasia, n = 44). Ten of 64 had familial FTD, with mutations in GRN (n = 3), MAPT (n = 4), or C9orf72 (n = 3). Fifteen of 64 had neurodegenerative biomarkers consistent with AD pathology (11 of whom had logopenic variant PPA). Levels were compared using multivariable linear regressions. RESULTS: CSF sTREM2 levels did not differ between FTD and controls or between clinical subgroups. However, GRN mutation carriers had higher levels than controls (mean ([SD] = 9.7 [2.9] vs. 6.8 [1.6] ng/ml; P = 0.028) and MAPT (3.9 [1.5] ng/ml; P = 0.003] or C9orf72 [4.6 [1.8] ng/ml; P = 0.006) mutation carriers. Individuals with AD-like CSF had higher sTREM2 levels than those with non-AD-like CSF (9.0 [3.6] vs. 6.9 [3.0] ng/ml; P = 0.029). CSF sTREM2 levels were associated with T-tau levels in control and FTD groups and also with P-tau in those with FTD and AD-like CSF. CSF sTREM2 levels were influenced by both age and disease duration in FTD. CONCLUSIONS: Although CSF sTREM2 levels are not raised in FTD overall or in a particular clinical subtype of FTD, levels are raised in familial FTD associated with GRN mutations and in FTD syndromes due to AD pathology. Because CSF sTREM2 levels correlate with a marker of neuronal injury (T-tau), sTREM2 should be explored as a biomarker of disease intensity in future longitudinal studies of FTD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-018-0405-8

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Comparison of CSF sTREM2 levels between groups and subgroups. Graphs show how CSF sTREM2 levels differ across (a) control and dementia (overall FTD, containing bvFTD and PPA) groups; (b) controls and clinical subgroups; (c) controls and genetic subgroups; and (d) controls and CSF biomarker-defined dementia subgroups (pathological subgroups). AD biomarker-negative dementia: CSF T-tau/Aβ42 ratio < 1.0; AD biomarker-positive dementia: CSF T-tau/Aβ42 ratio > 1.0. Horizontal bars show mean CSF sTREM2 levels and upper and lower 95% CIs for each group. *P < 0.05, **P < 0.01. Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, bvFTD Behavioural variant frontotemporal dementia, C9orf72 Chromosome 9 open reading frame 72 gene, FTD Frontotemporal dementia, CSF Cerebrospinal fluid, GRN Progranulin gene, lvPPA Logopenic variant primary progressive aphasia, MAPT Microtubule-associated protein tau gene, nfvPPA Non-fluent variant primary progressive aphasia, PPA-NOS Primary progressive aphasia not otherwise specified, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, svPPA Semantic variant primary progressive aphasia, T-tau Total tau
Fig. 1 Comparison of CSF sTREM2 levels between groups and subgroups. Graphs show how CSF sTREM2 levels differ across (a) control and dementia (overall FTD, containing bvFTD and PPA) groups; (b) controls and clinical subgroups; (c) controls and genetic subgroups; and (d) controls and CSF biomarker-defined dementia subgroups (pathological subgroups). AD biomarker-negative dementia: CSF T-tau/Aβ42 ratio < 1.0; AD biomarker-positive dementia: CSF T-tau/Aβ42 ratio > 1.0. Horizontal bars show mean CSF sTREM2 levels and upper and lower 95% CIs for each group. *P < 0.05, **P < 0.01. Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, bvFTD Behavioural variant frontotemporal dementia, C9orf72 Chromosome 9 open reading frame 72 gene, FTD Frontotemporal dementia, CSF Cerebrospinal fluid, GRN Progranulin gene, lvPPA Logopenic variant primary progressive aphasia, MAPT Microtubule-associated protein tau gene, nfvPPA Non-fluent variant primary progressive aphasia, PPA-NOS Primary progressive aphasia not otherwise specified, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, svPPA Semantic variant primary progressive aphasia, T-tau Total tauCC BY · PubMed Central
Fig. 2 Relationship between CSF sTREM2 and CSF neurodegenerative biomarker levels. Graphs show associations between CSF sTREM2 and CSF T-tau (a), P-tau (b) and Aβ42 (c) levels for control and dementia groups, and between CSF sTREM2 levels and CSF T-tau (d), P-tau (e) and Aβ42 (f) levels for the control group and dementia subgroups defined by CSF biomarker status (pathological subgroups). AD biomarker-negative dementia: CSF T-tau/Aβ42 ratio < 1.0; AD biomarker-positive dementia: CSF T-tau/Aβ42 ratio > 1.0. Lines are group regression lines adjusted for age and sex (controls) and age, sex and disease duration (overall dementia group and biomarker-defined dementia subgroups). See main text for individual β and P values for each association. Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, CSF Cerebrospinal fluid, P-tau tau phosphorylated at position threonine-181, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, T-tau Total tau
Fig. 2 Relationship between CSF sTREM2 and CSF neurodegenerative biomarker levels. Graphs show associations between CSF sTREM2 and CSF T-tau (a), P-tau (b) and Aβ42 (c) levels for control and dementia groups, and between CSF sTREM2 levels and CSF T-tau (d), P-tau (e) and Aβ42 (f) levels for the control group and dementia subgroups defined by CSF biomarker status (pathological subgroups). AD biomarker-negative dementia: CSF T-tau/Aβ42 ratio < 1.0; AD biomarker-positive dementia: CSF T-tau/Aβ42 ratio > 1.0. Lines are group regression lines adjusted for age and sex (controls) and age, sex and disease duration (overall dementia group and biomarker-defined dementia subgroups). See main text for individual β and P values for each association. Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, CSF Cerebrospinal fluid, P-tau tau phosphorylated at position threonine-181, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, T-tau Total tauCC BY · PubMed Central
Fig. 3 Relationship between CSF sTREM2 levels and age and disease duration at CSF collection. Graphs show CSF sTREM2 versus age (a) and disease duration (b and c) at CSF collection for the whole cohort (a, dotted line), dementia and control groups (a and b), and dementia subgroups defined by CSF biomarker status (c). Lines in (a) are group regression lines adjusted for sex (whole cohort and controls) and sex and disease duration (dementia group). Line in (b) is group regression line for dementia group adjusted for age and sex. Lines in (c) are group regression lines adjusted for age and sex for each CSF biomarker-defined dementia subgroup. AD biomarker-negative dementia: CSF T-tau/Aβ42 ratio < 1.0; AD biomarker-positive dementia: CSF T-tau/Aβ42 ratio > 1.0. See main text for individual β and P values for each association. Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, bvFTD Behavioural variant frontotemporal dementia, CSF Cerebrospinal fluid, lvPPA Logopenic variant primary progressive aphasia, nfvPPA Non-fluent variant primary progressive aphasia, PPA-NOS Primary progressive aphasia not otherwise specified, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, svPPA Semantic variant primary progressive aphasia, T-tau Total tau
Fig. 3 Relationship between CSF sTREM2 levels and age and disease duration at CSF collection. Graphs show CSF sTREM2 versus age (a) and disease duration (b and c) at CSF collection for the whole cohort (a, dotted line), dementia and control groups (a and b), and dementia subgroups defined by CSF biomarker status (c). Lines in (a) are group regression lines adjusted for sex (whole cohort and controls) and sex and disease duration (dementia group). Line in (b) is group regression line for dementia group adjusted for age and sex. Lines in (c) are group regression lines adjusted for age and sex for each CSF biomarker-defined dementia subgroup. AD biomarker-negative dementia: CSF T-tau/Aβ42 ratio < 1.0; AD biomarker-positive dementia: CSF T-tau/Aβ42 ratio > 1.0. See main text for individual β and P values for each association. Aβ42 β-Amyloid 1–42, AD Alzheimer’s disease, bvFTD Behavioural variant frontotemporal dementia, CSF Cerebrospinal fluid, lvPPA Logopenic variant primary progressive aphasia, nfvPPA Non-fluent variant primary progressive aphasia, PPA-NOS Primary progressive aphasia not otherwise specified, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, svPPA Semantic variant primary progressive aphasia, T-tau Total tauCC BY · PubMed Central
Fig. 4 Relationship between CSF sTREM2 levels and age and disease duration at CSF collection in clinical subtypes of FTD. Graphs show CSF sTREM2 versus age (a) and disease duration (b) at CSF collection for each clinical subgroup. Lines in (a) are group regression lines adjusted for sex and disease duration; lines in (b) are group regression lines adjusted for age and sex. See main text for individual β and P values for each association. bvFTD Behavioural variant frontotemporal dementia, FTD Frontotemporal dementia, CSF Cerebrospinal fluid, lvPPA Logopenic variant primary progressive aphasia, nfvPPA Non-fluent variant primary progressive aphasia, PPA-NOS Primary progressive aphasia not otherwise specified, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, svPPA Semantic variant primary progressive aphasia
Fig. 4 Relationship between CSF sTREM2 levels and age and disease duration at CSF collection in clinical subtypes of FTD. Graphs show CSF sTREM2 versus age (a) and disease duration (b) at CSF collection for each clinical subgroup. Lines in (a) are group regression lines adjusted for sex and disease duration; lines in (b) are group regression lines adjusted for age and sex. See main text for individual β and P values for each association. bvFTD Behavioural variant frontotemporal dementia, FTD Frontotemporal dementia, CSF Cerebrospinal fluid, lvPPA Logopenic variant primary progressive aphasia, nfvPPA Non-fluent variant primary progressive aphasia, PPA-NOS Primary progressive aphasia not otherwise specified, sTREM2 Soluble triggering receptor expressed on myeloid cells 2, svPPA Semantic variant primary progressive aphasiaCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 62

Metadata

Authors
Woollacott, I. O. C., Nicholas, J. M., Heslegrave, A., Heller, C., Foiani, M. S., Dick, K. M., Russell, L. L., Paterson, R. W., Keshavan, A., Fox, N. C., Warren, J. D., Schott, J. M., Zetterberg, H., & Rohrer, J. D.
Affiliations
  • UCL Queen Square Institute of Neurology (GB)
  • London School of Hygiene & Tropical Medicine (GB)
  • UK Dementia Research Institute (GB)
  • Sahlgrenska University Hospital (SE)
Corresponding author
Rohrer, Jonathan D.
Venue
Alzheimer's Research & Therapy
Published
2018-08-16
Volume
10
Issue
1
Pages
79-79
ISSN
1758-9193 (ISSN-L)
OpenAlex
W2885700079
Cited by
62
References
48
Citations by year
2026: 1 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 9 · 2021: 5 · 2020: 10 · 2019: 13 · 2018: 2
FWCI
5.90
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Medical Research Council
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
soluble TREM2, frontotemporal dementia, cerebrospinal fluid biomarkers, progranulin mutations, MAPT mutations, C9orf72 mutation, Alzheimer's disease pathology, primary progressive aphasia, behavioral variant frontotemporal dementia, tau phosphorylation, amyloid-beta 42, microglial activation, neuroinflammation, familial frontotemporal dementia
MeSH terms
C9orf72 Protein, Age Factors, Aged, Female, Gene Expression Regulation, Humans, Male, Membrane Glycoproteins, Middle Aged, Peptide Fragments, Phosphorylation, Receptors, Immunologic, Cohort Studies, Amyloid beta-Peptides, tau Proteins, Statistics, Nonparametric, Aphasia, Primary Progressive, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. https://app.cochat.ai/papers/10.1186/s13195-018-0405-8
The paper
Woollacott, I. O. C., Nicholas, J. M., Heslegrave, A., Heller, C., Foiani, M. S., Dick, K. M., Russell, L. L., Paterson, R. W., Keshavan, A., Fox, N. C., Warren, J. D., Schott, J. M., Zetterberg, H., & Rohrer, J. D. (2018). Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-018-0405-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.